Expression of exon 5 deleted estrogen receptor variant messenger RNA in human uterine myometrium and leiomyoma

Journal of Steroid Biochemistry and Molecular Biology

Volumn 67, Issue 1, 1998, Pages 9-16

  Mito, Kazuko ^a   Tamura, Takaya ^a   Hosokawa, Kenichi ^a   Kondo, Tokumasa ^a   Yamamoto, Takara ^a   Honjo, Hideo ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; MESSENGER RNA;

ARTICLE; BINDING AFFINITY; ENZYME ACTIVITY; ESTROGEN BINDING; EXON; GENE DELETION; GENE EXPRESSION REGULATION; GROWTH INHIBITION; HUMAN; HUMAN TISSUE; MESSENGER RNA SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSACTIVATION; TUMOR GROWTH; UTERUS MYOMA;

ADULT; AGE FACTORS; CLONING, MOLECULAR; EXONS; FEMALE; HUMANS; LEIOMYOMA; MENOPAUSE; MENSTRUAL CYCLE; MENSTRUATION DISTURBANCES; MIDDLE AGED; MYOMETRIUM; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEQUENCE DELETION; UTERINE NEOPLASMS; VARIATION (GENETICS);

EID: 0031759454     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(98)00072-7     Document Type: Article

References (46)

1. Puzigaca Z., Prelevic G. M. and Sretenovic Z., Differential reduction in the volume of leiomyoma and uterus during buserelin treatment. Gynecol. Endocrinol. 8 (1994) 39-43.
2. Otubu J. A., Buttram V. C. and Besch P. K., Unconjugated steroids in leiomyomas and tumor-bearing myometrium. Am. J. Obstet. Gynecol. 143 (1982) 130-133.
3. Yamamoto T., Takamori K. and Okada H., Estrogen biosynthesis in leiomyomas and myometrium of the uterus. Horm. Metab. Res. 16 (1984) 678-679.
4. Lumsden M. A., West C. P., Hawkins R. A., Bramley T. A. and Rumgay L., The binding of steroids to myometrium and leiomyomata(fibroids) in women treated with the gonadotropin-releasing hormone agonist Zoladex (ICI 118630). J. Endocrinol. 121 (1989) 389-396.
5. Brandon D. D., Erickson T. E., Keenan E. J., Strawn E. Y., Novy M. J., Burry K. A., Warner C. and Clinton G. M., Estrogen receptor gene expression in human uterine leiomyomata. J. Clin. Endocrinol. Metab. 80 (1995) 1876-1881.
6. Sadan O., van Iddekinge B., van Gelderen C. J., Savage N., Becker P. J., van der Walt L. A. and Robinson M., Oestrogen and progesterone receptor concentrations in leiomyoma and normal myometrium. Ann. Clin. Biochem. 24 (1987) 263-267.
7. Chrapusta S., Konopka B., Paszko Z., Sieinski W. and Szamborski J., Immunoreactive and estrogen-binding estrogen receptors, and progestin receptor levels in uterine leiomyomata and their parental myometrium. Eur. J. Gynaecol. Oncol. 11 (1990) 275-281.
8. Vollenhoven B. J., Pearce P., Herington A. C. and Heary D. L., Steroid receptor binding and messenger RNA expression in fibroids from untreated and gonadotrophin-releasing hormone agonist pretreated women. Clin. Endocrinol. (Oxf.) 40 (1994) 537-544.
9. Kornyei J., Csermery T., Szekely J. A. and Vertes M., Two types of nuclear oestradiol binding sites in human myometrium and leiomyoma during the menstrual cycle. Exp. Clin. Endocrinol. Biol. 87 (1986) 256-264.
10. Sluyser M., Mutations in the estrogen receptor gene. Human Mutat. 6 (1995) 97-103.
11. Pink J. J., Wu S.-Q., Woplf D. M., Bilimoria M. M. and Jordan V. C., A novel 80 kDa human estrogen receptor containing a duplication of exons 6 and 7. Nucl. Acids Res. 24 (1996) 962-969.
12. Fuqua S. A. W., Fitzgerald S. D., Chamness G. C., Tandon A. K., McNonnell D. P., Nawaz Z., O'Maalley B. W. and McGuire W. L., Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res. 51 (1991) 105-109.
13. Castles C. G., Fuqua S. A., Klotz D. M. and Hill S. M., Expression of a constitutively active estrogen receptor variant in the estrogen receptor-negative BT-20 human breast cancer cell line. Cancer Res. 53 (1993) 5934-5939.
14. Koehorst S. G. A., Cox J. J., Donker G. H., Lopes da Silva S., Burbach J. P. H., Thijssen J. H. H. and Blankenstein M. A., Functional analysis of an alternatively spliced estrogen receptor lacking exon 4 isolated from MCF-7 breast cancer cells and meningioma tissue. Mol. Cell. Endocrinol. 101 (1994) 237-245.
15. Villa E., Camellini L., Dugani A., Zucchi F., Grottola A., Merighi A., Buttafoco P., Losi L. and Manenti F., Variant estrogen receptor messenger RNA species detected in human primary hepatocellular carcinoma. Cancer Res. 55 (1995) 498-500.
16. Koehorst S. G. A., Jacobs H. M., Tilanus M. G. J., Bouwens A. G. M., Thijssen J. H. H. and Blankenstein M. A., Aberrant oestrogen receptor species in human meningioma tissue. J. Steroid Biochem. Mol. Biol. 43 (1992) 57-61.
17. Blankenstein M. A., Koehorst S. G., van der Kallen C. J., Jacobs H. M., van Spriel A. B., Donker G. H., van't Verlaat J. W., Blaauw G. and Thijssen J. H., Oestrogen receptor independent expression of progestin receptors in human meningioma: a review. J. Steroid Biochem. Mol. Biol. 53 (1995) 361-365.
18. Hirata S., Yamada-Mouri N., Nara M., Takizawa M., Ito H. and Kato J., Presence of alternatively spliced-estrogen receptor mRNA variants in normal human uterine endometrium and endometrial cancer. Endocrinol. J. 42 (1995) 289-293.
19. Fujimoto J., Ichigo S., Hirose R., Hori M. and Tamaya T., Expression of estrogen receptor exon 5 splicing variant (ER E5SV) mRNA in gynaecological cancers. J. Steroid Biochem. Mol. Biol. 60 (1997) 25-30.
20. Greene G. L., Gilna P., Waterfield M., Baker A., Hort Y. and Shine J., Sequence and expression of human estrogen receptor complementary DNA. Science 231 (1986) 1150-1154.
21. Tsi J. Y., Sun X. H., Kao T. H., Reece K. S. and Wu R., Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs: genomic complexity and molecular evolution of the gene. Nucl. Acids Res. 13 (1985) 2485-2502.
22. Kumar V., Green Stack G., Berry M., Jin J. R. and Chambon P., Functional domains of the human estrogen receptor. Cell 51 (1987) 941-951.
23. Kumar V. and Chambon P., The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell 55 (1988) 145-156.
24. Ponglikitmongkol M., Green S. and Chambon P., Genomic organization of the human oestrogen receptor gene. EMBO J. 7 (1988) 3385-3388.
25. Tora L., White J., Brou C., Tasset D., Webster N., Scheer E. and Chambon P., The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 59 (1989) 477-487.
26. Limieux P. and Fuqua S., The role of the estrogen receptor in tumor progression. J. Steroid Biochem. Mol. Biol. 56 (1996) 87-91.
27. Kedar, R. P., Bourne, T. H., Powles, T. J., Collins, W. P., Ashley, S. E., Cosgrove, D. O. and Campell, S., Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet, 1994, 343, 1318-21-752.
28. Jamil A., Croxtall J. D. and White J. O., The effect of antioestrogens on cell growth and progesterone receptor concentration in human endometrial cancer cells (Ishikawa). J. Mol. Endocrinol. 6 (1991) 215-221.
29. Huynh H. T. and Pollak M., Insulin-like growth factor I gene expression in the uterus is stimulated by tamoxifen and inhibited by the pure antiestrogen ICI 182780. Cancer Res. 53 (1993) 5585-5588.
30. Daffada A. A. I., Johonston S. R. D., Nicolls J. and Dowsett M., Detention of wild type and exon-5 deleted splice variant oestrogen receptor (ER) mRNA in ER-positive and negative breast cancer cell lines by reverse transcription/polymerase chain reaction. J. Mol. Endocrinol. 13 (1994) 265-273.
31. Zhang Q. X., Hilsenbeck S. G., Fuqua S. A. W. and Borg A., Multiple splicing variants of the estrogen receptor are present in individual human breast tumors. J. Steroid Biochem. Mol. Biol 59 (1996) 251-260.
32. Strawn E. Y. Jr., Novy M. J., Burry K. A. and Bethea C. L., Insulin-like growth factor I promotes leiomyoma cell growth in vitro. Am. J. Obstet. Gynecol. 172 (1995) 1837-1844.
33. Vollenhoven B. J., Herington A. C. and Healy D. L., Epidermal growth factor and transforming growth factor-beta in uterine fibroids and myometrium. Gynecol. Obstet. Invest. 40 (1995) 120-124.
34. Dou Q., Zhao Y., Tarnuzzer R. W., Rong H., Williams R. S., Schultz G. S. and Chegini N., Suppression of transforming growth factor-beta (TGF beta) and TGF beta receptor messenger ribonucleic acid and protein expression in leiomyomata in women receiving gonadotropin-releasing hormone agonist therapy. J. Clin. Endocrinol. Metab. 81 (1996) 3222-3230.
35. Ignar-Trowbridge D. M., Pimentel M., Parker M. G., McLachlan J. A. and Korach K. S., Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol. Endocrinology 137 (1996) 1735-1744.
36. Kato S., Endoh H., Masuhiro Y., Kitamoto T., Uchiyama S., Sasaki H., Masusige S., Gotoh Y., Nishida E., Kawashima H., Metzger D. and Chambon P., Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270 (1995) 1491-1494.
37. Bunone G., Briand P. A., Miksicek R. J. and Picard D., Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 15 (1996) 2174-2183.
38. Fernandez-Montoli M. E., Diez-Gibert O., Samanniego J. M., Balaguero L. and Navarro M. A., Total and unbound cytosolic estrogen and progesterone receptors in myometrium and fibroid after gonadotropin-releasing hormone agonist treatment. Fertil. Steril. 63 (1995) 522-527.
39. Vij U., Murugesan K., Laumas K. R. and Farooq A., Progestin and antiprogestin interactions with progesterone receptors in human myomas. Int. J. Gynaecol. Obstet. 31 (1990) 347-353.
40. Murphy A. A., Kettel L. M., Morales A. J., Roberts V. J. and Yen S. S., Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J. Clin. Endocrinol Metab. 76 (1993) 513-517.
41. Zhang Q. X., Borg A. and Fuqua S. A. W., An exon-5 deletion variant of the estrogen receptor frequently coexpressed with wild-type estrogen receptor in human breast cancer. Cancer Res. 53 (1993) 5882-5884.
42. McGuire W. L., Chamness G. C. and Fqua S. A., Estrogen receptor variants in clinical breast cancer. Mol. Endocrinol. 5 (1991) 1571-1577.
43. Rea D. and Parker M. G., Effects of an exon 5 variant of the estrogen receptor in MCF-7 breast cancer cell. Cancer Res. 56 (1996) 1556-1563.
44. Soules M. R. and McCarty K. S., Leiomyomas: Steroid receptor content. Variation within normal menstrual cycles. Am. J. Obstet. Gynecol. 143 (1982) 6-11.
45. Ochiai K., Cyclic variation and distribution in the concentration of cytosol estrogen and progesterone receptors in the normal human uterus and myoma. Acta Obst. Gynaec. Jpn. 32 (1980) 945-952.
46. Murphy L. C., Dotzlaw H., Leygue E., Douglas D., Coutts A. and Watson P. H., Estrogen receptor variants and mutations. J. Steroid Biochem. Mol. Biol. 62 (1997) 363-372.